Edgewise Therapeutics, Inc.
EWTX
$33.76
-$0.25-0.74%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 11.46M | 12.39M | 9.38M | 9.05M | 9.20M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 54.12M | 55.98M | 46.86M | 42.61M | 45.96M |
| Operating Income | -54.12M | -55.98M | -46.86M | -42.61M | -45.96M |
| Income Before Tax | -49.01M | -50.22M | -40.67M | -36.12M | -40.80M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -49.01M | -50.22M | -40.67M | -36.12M | -40.80M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -49.01M | -50.22M | -40.67M | -36.12M | -40.80M |
| EBIT | -54.12M | -55.98M | -46.86M | -42.61M | -45.96M |
| EBITDA | -53.58M | -55.45M | -46.34M | -42.09M | -45.45M |
| EPS Basic | -0.46 | -0.47 | -0.39 | -0.34 | -0.43 |
| Normalized Basic EPS | -0.29 | -0.30 | -0.24 | -0.22 | -0.27 |
| EPS Diluted | -0.46 | -0.47 | -0.39 | -0.34 | -0.43 |
| Normalized Diluted EPS | -0.29 | -0.30 | -0.24 | -0.22 | -0.27 |
| Average Basic Shares Outstanding | 107.12M | 106.01M | 105.49M | 104.94M | 95.13M |
| Average Diluted Shares Outstanding | 107.12M | 106.01M | 105.49M | 104.94M | 95.13M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |